Literature DB >> 11786308

Cannabinoids: a real prospect for pain relief?

Leslie Iversen1, Victoria Chapman.   

Abstract

Research on the therapeutic potential of cannabinoids has grown dramatically over the past few years. Recent advances include evidence that cannabinoid agonists are antihyperalgesic and antiallodynic in models of neuropathic pain. Development of novel cannabinoid agonists and cannabinoid preparations that are antinociceptive has important implications for the therapeutic use of this class of drugs.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11786308     DOI： 10.1016/s1471-4892(01)00120-5

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  43 in total

Review 1.  Putative therapeutic targets in the treatment of visceral hyperalgesia.

Authors:  S Collins
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

2.  Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.

Authors:  C-L Chin; A E Tovcimak; V P Hradil; T R Seifert; P R Hollingsworth; P Chandran; C Z Zhu; D Gauvin; M Pai; J Wetter; G C Hsieh; P Honore; J M Frost; M J Dart; M D Meyer; B B Yao; B F Cox; G B Fox
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

3.  Novel endogenous peptide agonists of cannabinoid receptors.

Authors:  Ivone Gomes; Julia S Grushko; Urszula Golebiewska; Sascha Hoogendoorn; Achla Gupta; Andrea S Heimann; Emer S Ferro; Suzanne Scarlata; Lloyd D Fricker; Lakshmi A Devi
Journal:  FASEB J       Date:  2009-04-20       Impact factor: 5.191

4.  Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing.

Authors:  E Palazzos; V de Novellis; I Marabese; F Rossi; S Maione
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

5.  Hemopressin is an inverse agonist of CB1 cannabinoid receptors.

Authors:  Andrea S Heimann; Ivone Gomes; Camila S Dale; Rosana L Pagano; Achla Gupta; Laura L de Souza; Augusto D Luchessi; Leandro M Castro; Renata Giorgi; Vanessa Rioli; Emer S Ferro; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

6.  Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors.

Authors:  S Maione; L De Petrocellis; V de Novellis; A Schiano Moriello; S Petrosino; E Palazzo; F Sca Rossi; D F Woodward; V Di Marzo
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

7.  An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain.

Authors:  Yong Fang Zhu; Katja Linher-Melville; Mohammad Javad Niazmand; Manu Sharma; Ayesha Shahid; Kan Lun Zhu; Natalka Parzei; Jesse Sidhu; Christeene Haj; Raphael Mechoulam; Gurmit Singh
Journal:  Br J Pharmacol       Date:  2020-03-08       Impact factor: 8.739

8.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

Review 9.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

Review 10.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.